In a landmark collaboration, Ramathibodi Hospital and Samitivej Hospital have announced a joint effort to push the boundaries of cancer treatment in Thailand. Their focus: developing and expanding access to cell and gene therapies designed to combat some of the most challenging blood cancers, including leukaemia and lymphoma.

Cell and gene therapy has emerged as one of the most promising frontiers in modern medicine. Unlike traditional chemotherapy or radiation, these treatments target cancer at the molecular level—modifying a patient’s own immune cells or genetic makeup to recognize and destroy cancer cells more effectively. For patients who have not responded to conventional treatments, this approach can represent a new lifeline.

The partnership between Ramathibodi and Samitivej combines the strengths of both institutions. Ramathibodi brings decades of expertise as a leading academic hospital, with research infrastructure and access to clinical trial networks. Samitivej, a top private hospital group, contributes advanced medical facilities and international-standard patient care. Together, they aim to accelerate research, expand clinical applications, and eventually make these cutting-edge therapies more accessible to Thai patients.

Experts believe this collaboration could also establish Thailand as a regional hub for advanced cancer care. By investing in training, technology, and international partnerships, the two hospitals are positioning the country to play a greater role in global innovation against cancer.

For patients and families facing leukaemia and lymphoma, the initiative delivers a message of hope: that the future of cancer care in Thailand is not only about extending life, but improving its quality through groundbreaking science and compassionate care.